<DOC>
	<DOC>NCT01985165</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Imrecoxib in the treatment of patients with knee osteoarthritis.</brief_summary>
	<brief_title>A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Aged form 18 years to 75 years old Diagnosed with osteoarthritis of the knee according to the American College of Rheumatology Functional capacity class of ⅠⅢ Unstable angina History of myocardial infarction within the last 6 months Stroke in the 6 months before screening New York Heart Association class ⅢⅣ congestive heartfailure Systolic blood pressure＞180mmHg,and/or Diastolic blood pressure＞100mmHg Peptic ulcer Known contraindications to nonsteroidal antiinflammatory drug（NSAID） Received aspirin within 3 days of baseline visit Aspirin dosage&gt;150mg/d Known to be Allergic to sulfa and COX2 inhibitors Pregnancy or lactation Glutamicoxaloacetic transaminase and/or glutamicpyruvic transaminase＞2 times upper limit of normal Blood urine nitrogen＞1.5 times upper limit of normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>